A landmark Phase III study has demonstrated that a single, personalized injection can slash the chance of cancer returning by 50%, marking the world’s first successful customized therapeutic tumor trial. Researchers at Peking University used a novel nanomaterial that triggers a form of cell death called pyroptosis, releasing highly immunogenic vesicles that prime the immune system to attack tumors. The treatment, dubbed SPEN, was administered systemically and showed strong safety and efficacy signals, paving the way for market approval as early as 2027. The breakthrough sits alongside several other exciting advances in cancer immunotherapy. A multi‑subtype vaccine targeting KRAS mutations, combined with checkpoint inhibitors, extended disease‑free survival for patients with resected pancreatic cancer. Yale and Dana‑Farber scientists reported a personalized renal‑cell‑carcinoma vaccine that kept patients cancer‑free for three years after a single dose. Meanwhile, Tsinghua University unveiled an intranasal RNA vaccine that delivers circular RNA via lipid nanoparticles, achieving potent anti‑lung‑cancer effects with minimal side effects. Collectively, these studies highlight a shift toward highly tailored, minimally invasive cancer vaccines that harness the body’s own defenses, offering new hope for patients across a range of tumor types.
Read more